698 related articles for article (PubMed ID: 21632984)
1. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Fornoni A; Sageshima J; Wei C; Merscher-Gomez S; Aguillon-Prada R; Jauregui AN; Li J; Mattiazzi A; Ciancio G; Chen L; Zilleruelo G; Abitbol C; Chandar J; Seeherunvong W; Ricordi C; Ikehata M; Rastaldi MP; Reiser J; Burke GW
Sci Transl Med; 2011 Jun; 3(85):85ra46. PubMed ID: 21632984
[TBL] [Abstract][Full Text] [Related]
2. Rituximab's new therapeutic target: the podocyte actin cytoskeleton.
Chan AC
Sci Transl Med; 2011 Jun; 3(85):85ps21. PubMed ID: 21632983
[TBL] [Abstract][Full Text] [Related]
3. Rituximab treatment prevents the early development of proteinuria following pig-to-baboon xeno-kidney transplantation.
Tasaki M; Shimizu A; Hanekamp I; Torabi R; Villani V; Yamada K
J Am Soc Nephrol; 2014 Apr; 25(4):737-44. PubMed ID: 24459229
[TBL] [Abstract][Full Text] [Related]
4. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome.
Watanabe S; Hirono K; Aizawa T; Tsugawa K; Joh K; Imaizumi T; Tanaka H
Clin Exp Nephrol; 2021 Jan; 25(1):44-51. PubMed ID: 32946006
[TBL] [Abstract][Full Text] [Related]
5. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes.
Takahashi Y; Ikezumi Y; Saitoh A
Nephrology (Carlton); 2017 Jan; 22(1):49-57. PubMed ID: 26833819
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome.
Watanabe S; Tsugawa K; Tsuruga K; Imaizumi T; Tanaka H
Pediatr Int; 2017 Oct; 59(10):1112-1115. PubMed ID: 29081073
[TBL] [Abstract][Full Text] [Related]
7. Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis.
Kachurina N; Chung CF; Benderoff E; Babayeva S; Bitzan M; Goodyer P; Kitzler T; Matar D; Cybulsky AV; Alachkar N; Torban E
Am J Physiol Renal Physiol; 2016 May; 310(10):F1148-56. PubMed ID: 26719363
[TBL] [Abstract][Full Text] [Related]
8. Fatal late-onset Pneumocystis pneumonia after rituximab: administration for posttransplantation recurrence of focal segmental glomerulosclerosis--case report.
Dęborska-Materkowska D; Kozińska-Przybył O; Mikaszewska-Sokolewicz M; Durlik M
Transplant Proc; 2014 Oct; 46(8):2908-11. PubMed ID: 25380948
[TBL] [Abstract][Full Text] [Related]
9. The Importance of Sphingomyelin Phosphodiesterase Acid-Like 3b (SMPDL-3b) Levels in Kidney Biopsy Specimens of Children With Nephrotic Syndrome.
Kaya M; Girişgen İ; Yalçın N; Becerir T; Şenol H; Gülten G; Yüksel S
Fetal Pediatr Pathol; 2023 Dec; 42(6):936-949. PubMed ID: 37818552
[TBL] [Abstract][Full Text] [Related]
10. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuria in focal segmental glomerulosclerosis.
Chang JW; Pardo V; Sageshima J; Chen L; Tsai HL; Reiser J; Wei C; Ciancio G; Burke GW; Fornoni A
Transplantation; 2012 Jun; 93(12):1238-44. PubMed ID: 22499148
[TBL] [Abstract][Full Text] [Related]
11. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.
Ahmad A; Mitrofanova A; Bielawski J; Yang Y; Marples B; Fornoni A; Zeidan YH
FASEB J; 2017 Feb; 31(2):771-780. PubMed ID: 27836988
[TBL] [Abstract][Full Text] [Related]
12. Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis.
Otalora L; Chavez E; Watford D; Tueros L; Correa M; Nair V; Ruiz P; Wahl P; Eddy S; Martini S; Kretzler M; Burke GW; Fornoni A; Merscher S
PLoS One; 2019; 14(10):e0222948. PubMed ID: 31581251
[TBL] [Abstract][Full Text] [Related]
13. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
[TBL] [Abstract][Full Text] [Related]
14. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic tumor necrosis factor-α pathway is activated in a subset of patients with focal segmental glomerulosclerosis.
Chung CF; Kitzler T; Kachurina N; Pessina K; Babayeva S; Bitzan M; Kaskel F; Colmegna I; Alachkar N; Goodyer P; Cybulsky AV; Torban E
PLoS One; 2019; 14(5):e0216426. PubMed ID: 31095586
[TBL] [Abstract][Full Text] [Related]
16. Protecting Podocytes: A Key Target for Therapy of Focal Segmental Glomerulosclerosis.
Campbell KN; Tumlin JA
Am J Nephrol; 2018; 47 Suppl 1(Suppl 1):14-29. PubMed ID: 29852493
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen links podocyte injury with Toll-like receptor 4 and is associated with disease activity in FSGS patients.
Wang H; Zheng C; Xu X; Zhao Y; Lu Y; Liu Z
Nephrology (Carlton); 2018 May; 23(5):418-429. PubMed ID: 28407405
[TBL] [Abstract][Full Text] [Related]
18. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation.
Tsagalis G; Psimenou E; Nakopoulou L; Laggouranis A
Artif Organs; 2011 Apr; 35(4):420-5. PubMed ID: 20637013
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis.
Kumar J; Shatat IF; Skversky AL; Woroniecki RP; Del Rio M; Perelstein EM; Johnson VL; Mahesh S
Pediatr Nephrol; 2013 Feb; 28(2):333-8. PubMed ID: 23052653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
